Quick access to main page (top) Direct access to main contents Quick access to main page (bottom)
로고

Roche’s $7.6 Billion Drug Just Hit a Wall—Here’s Why That Matters

Daniel Kim Views  

6
Medical Today
Medical Today

Roche reported that in a clinical trial, Ocrevus, a treatment for multiple sclerosis, did not exhibit any better effects than the standard dose.

Roche’s attempt to increase the use of its best-selling medication has failed.

According to Roche, a late-stage study revealed that a dose two to three times greater than the typical 600 mg version did not demonstrate any extra benefit in delaying the progression of relapsing multiple sclerosis.

In the meantime, Ocrevus is Roche’s top-selling medication and a key factor in the company’s expansion. Sales are expected to reach approximately 7.59 billion USD in 2024.

Daniel Kim
content@viewusglobal.com
More Articles

Comments0

300

Comments0

[LIFESTYLE] Latest Stories

  • Diabetes Is Rising Fast in Young People — Here's What You Can Do
  • We Tried a Week of Nothing but Protein Shakes—Here’s What Happened
  • New Study Finds Gene That Could Ease Allergies in Kid
  • Purple Carrots Are Making a Comeback—and Here’s Why You Should Care
  • Beat Those Chills Without Pills: 5 Things You Can Do at Home
  • New Study Says You Can Slim Down and Save Your Bones—Here’s How

[LIFESTYLE] Popular Now

  • Diabetes Is Rising Fast in Young People — Here's What You Can Do
  • We Tried a Week of Nothing but Protein Shakes—Here’s What Happened
  • New Study Finds Gene That Could Ease Allergies in Kid
  • Purple Carrots Are Making a Comeback—and Here’s Why You Should Care
  • Beat Those Chills Without Pills: 5 Things You Can Do at Home
  • New Study Says You Can Slim Down and Save Your Bones—Here’s How

Hot Topics

로고
Advertisements
  • Company Name: Global Sun Publishing
  • Address: 6th floor, 20, 380, Daejongro, Jung-gu, Daejeon
  • Business Registration Number : 774-54-09675
  • Contact Us : +82 70 6585 4343
  • Youth Protection Manager : Jee Eun Sung
  • Publisher : Park Ji Min
  • Editor : Choi Sang Hee

All content of ViewusGlobal is protected by copyright law, and unauthorized reproduction, copying, distribution, etc. are prohibited.
© Copyright by ViewusGlobal. All Rights Reserved.